Skip to content
mapperlab
← Dashboard
Stock

INO

INOVIO PHARMACEUTICALS, INC.
Latest close $1.225 of 27 marquee funds currently hold2 CUSIPs mapped
Current holders
5
27 funds tracked
Ever held
8
Current + past
New this quarter
1
Exited this quarter
0

Marquee-fund ownership over time

Aug 14, 2020Aug 9, 2024Aug 14, 2025May 15, 2026
Now
5

This quarter's activity

New positions opened

Positions exited

None.

Current holders

Sorted by tenure (longest first)
FundEntry priceLatest closeReturn on entry
Renaissance Technologies$8.44$1.22-86%
Two Sigma Investments re-entered$7.82$1.22-84%
Millennium Management re-entered$7.82$1.22-84%
Citadel Advisors re-entered$2.15$1.22-43%
D.E. Shaw$2.05$1.22-40%

“Return on entry” is the price-only move from the fund's first disclosure to today — it ignores any adds, trims, or dividends. A fund that built its position over multiple quarters has a true cost basis somewhere between entry price and latest close; this figure is the upper bound.

Past holders

Funds that exited at some point
FundEntry → ExitReturn
AQR Capital Management→ $2.05+5%
Coatue Management—+0%
Maverick Capital—+0%

Insider activity

Form 4 — officers, directors, 10%+ owners

Filed within two business days of each transaction by anyone with material insider status at INOVIO PHARMACEUTICALS, INC.. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.

Filings · last 30d
15
Filings · last 90d
25
Total on file
483
Recent SEC buffer
Most recent
May 21, 2026

30d / 90d windows measured from May 21, 2026 — the most recent Form 4 on file — not from today.

Showing 15 of 483 recent Form 4 filings. Browse all on EDGAR ↗

Fundamentals

XBRL · INOVIO PHARMACEUTICALS, INC.

Annual figures sourced directly from INOVIO PHARMACEUTICALS, INC.'s 10-K / 10-Q filings via SEC EDGAR XBRL. Latest fiscal year and the year-over-year change, with up to ten years of history.

Revenue
$65.34K
FY2025-70% YoY
Net income
-$84.95M
FY2025+21% YoY
EPS (diluted)
$-1.81
FY2025+54% YoY
Free cash flow(?)
-$88.92M
FY2025+15% YoY

Recent SEC filings

10-K · 10-Q · 8-K · 13D/G · proxy

The most recent material filings for INOVIO PHARMACEUTICALS, INC. — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.

Trade history

Every open→close lifecycle across tracked funds
FundOpen dateClose dateOpen priceClose price / currentReturn
Citadel AdvisorsQ2 2026open$1.30$1.22-6%
D.E. ShawQ4 2025open$2.05$1.22-40%
Citadel AdvisorsQ3 2025Q1 2026$1.62$1.63+1%
Millennium ManagementQ3 2025open$1.62$1.22-25%
Two Sigma InvestmentsQ2 2025open$1.95$1.22-37%
AQR Capital ManagementQ2 2025Q4 2025$1.95$2.05+5%
Citadel AdvisorsQ1 2025Q2 2025$2.15$1.95-9%
Two Sigma InvestmentsQ3 2024Q1 2025$7.82$2.15-73%
Millennium ManagementQ3 2024Q1 2025$7.82$2.15-73%
Renaissance TechnologiesQ3 2024open$8.44$1.22-86%
Coatue ManagementQ3 2020Q3 2021$0.00—+0%
Maverick CapitalQ3 2020Q1 2021$0.00—+0%
Caveats
  • Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
  • Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
  • “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
  • Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
  • Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.